Previous 10 |
Assertio Therapeutics Inc (ASRT) Q4 2018 Earnings Conference Call March 6, 2019 04:30 p.m. ET Company Representatives Arthur Higgins - President, Chief Executive Officer Dan Peisert - Senior Vice President, Chief Financial Officer John Thomas - Senior Vice President of Investor R...
Assertio Therapeutics (NASDAQ: ASRT ): Q4 Non-GAAP EPS of $0.30 beats by $0.10 ; GAAP EPS of -$0.38 misses by $0.08 . More news on: Assertio Therapeutics Inc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
-- Reports Neurology Franchise Annual Net Sales of $110.3 million, at the High End of Guidance Range -- -- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance -- -- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales -- LA...
ABM , ASRT , BLDP , BREW , CBPO , DSGX , FTK , GWRE , HIIQ , WHD , YEXT For Seeking Alpha's full earnings season calendar, click here . More news on: ABM Industries Incorporated, Assertio Therapeutics Inc, Ballard Power Systems, Inc., Earnings news and commentary,
The broad market's down day notwithstanding, opioid drugmakers are under modest pressure in apparent response to a report that privately held Purdue Pharma is mulling a Chapter 11 bankruptcy filing to protect itself from the ~2,000 lawsuits against it related to its marketing practices for...
LAKE FOREST, Ill., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2018 financial results on Wednesday, March 6, 2019, after the close of markets. Following the announcement, the Company will host ...
The FDA accepts for review Assertio Therapeutic's (NASDAQ: ASRT ) marketing application seeking approval for its injectable formulation of long-acting cosyntropin (synthetic adrenocorticotropic hormone, or ACTH) as a diagnostic drug in screening for adrenocortical insufficiency. More new...
LAKE FOREST, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration (FDA) for its 505(b)(2) New Drug Application for its injectable formulation o...
LAKE FOREST, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Heather L. Mason has been appointed to the Company’s Board of Directors. Ms. Mason is a former executive vice president of Abbott Laboratories. “Heather is a...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...